Protocols

Low-profile BeyondSpring files for $100M IPO to back cancer work; Erytech hammered after it pulls marketing application

BeyondSpring Pharmaceuticals, a low-profile biotech registered in the Cayman Islands with offices in New York and China, has filed for a $100 million IPO. The company’s main focus is on plinabulin, a drug it in-licensed in 2013 and now plans to put it into a slate of late-stage studies for neutropenia as well as non-small cell lung cancer. Its work on NSCLC revolves around mid-stage data collected on a subset of patients. And now it’s looking for investor support to pay for the R&D. Here’s the F-1.

Erytech Pharma (Euronext Paris: ERYP) shares plunged 22% after the biotech announced it has decided to pull its marketing application at the EMA for its experimental treatment Graspa, developed for acute lymphoblastic leukemia. The biotech is looking for more time to answer a list of outstanding issues presented by regulators and now expects to re-file the app in mid-2017.

Israeli tech mogul Marius Nacht is raising a $100 million fund that will back a new wave of life sciences companies, reports Reuters. Orbimed is one of the busiest players in Israel’s growing biotech industry.

Biogen has named two new execs to help manage its hemophilia spinout, Rogerio Vivaldi, MD, will serve as executive vice president and chief global therapeutic operations officer of Bioverativ, and John T. Greene will serve as executive vice president and chief financial officer of the company. The spin-off of Bioverativ is on track to be completed in early 2017.


The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

BioNJ CEO Summit 2017

Immuno Oncology 360